WO2019093807A3 - Il-17a 에 특이적으로 결합하는 항체 및 이의 용도 - Google Patents

Il-17a 에 특이적으로 결합하는 항체 및 이의 용도 Download PDF

Info

Publication number
WO2019093807A3
WO2019093807A3 PCT/KR2018/013601 KR2018013601W WO2019093807A3 WO 2019093807 A3 WO2019093807 A3 WO 2019093807A3 KR 2018013601 W KR2018013601 W KR 2018013601W WO 2019093807 A3 WO2019093807 A3 WO 2019093807A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
binding fragment
binding specifically
antibody binding
Prior art date
Application number
PCT/KR2018/013601
Other languages
English (en)
French (fr)
Other versions
WO2019093807A2 (ko
Inventor
윤재봉
전은영
유석호
박재은
강원화
김혜난
김응철
김수영
임주리
조영규
박범찬
임정채
박영우
Original Assignee
주식회사 와이바이오로직스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 와이바이오로직스 filed Critical 주식회사 와이바이오로직스
Publication of WO2019093807A2 publication Critical patent/WO2019093807A2/ko
Publication of WO2019093807A3 publication Critical patent/WO2019093807A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

본 발명은 IL-17A에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터, 상기 벡터로 형질전환된 세포, 상기 항체 또는 이의 항원 결합 단편의 제조방법, 상기 항체 또는 이의 항원 결합 단편을 포함하는 항체-약물 접합체, 상기 항체 또는 이의 항원 결합 단편을 포함하는 이중항체 및 이의 암 또는 자가면역질환의 예방 또는 치료용 조성물에 관한 것이다.
PCT/KR2018/013601 2017-11-10 2018-11-09 Il-17a 에 특이적으로 결합하는 항체 및 이의 용도 WO2019093807A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170149362A KR102048475B1 (ko) 2017-11-10 2017-11-10 IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
KR10-2017-0149362 2017-11-10

Publications (2)

Publication Number Publication Date
WO2019093807A2 WO2019093807A2 (ko) 2019-05-16
WO2019093807A3 true WO2019093807A3 (ko) 2019-06-27

Family

ID=66438028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/013601 WO2019093807A2 (ko) 2017-11-10 2018-11-09 Il-17a 에 특이적으로 결합하는 항체 및 이의 용도

Country Status (2)

Country Link
KR (1) KR102048475B1 (ko)
WO (1) WO2019093807A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101158959B1 (ko) * 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-ｉｌ-17 항체
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
KR20160085793A (ko) * 2013-11-18 2016-07-18 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 Ｉｌ-17ａ 접합체 및 이의 용도
US20170022272A1 (en) * 2012-05-22 2017-01-26 Bristol-Myers Squibb Company Il-23 antibodies and methods of using the same
US20170198035A1 (en) * 2013-02-08 2017-07-13 Novartis Ag Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101158959B1 (ko) * 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-ｉｌ-17 항체
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
US20170022272A1 (en) * 2012-05-22 2017-01-26 Bristol-Myers Squibb Company Il-23 antibodies and methods of using the same
US20170198035A1 (en) * 2013-02-08 2017-07-13 Novartis Ag Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
KR20160085793A (ko) * 2013-11-18 2016-07-18 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 Ｉｌ-17ａ 접합체 및 이의 용도

Also Published As

Publication number Publication date
KR102048475B1 (ko) 2019-11-26
WO2019093807A2 (ko) 2019-05-16
KR20190053464A (ko) 2019-05-20

Similar Documents

Publication Publication Date Title
WO2019224711A3 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
WO2018089508A3 (en) Anti-cd47 antibodies
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2017079116A3 (en) Antibodies specifically binding pd-1 and tim-3 and their uses
WO2017059243A3 (en) Agonistic antibodies specifically binding human cd40 and methods of use
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
WO2018031490A3 (en) Anti-ox40 binding proteins
MX2019010922A (es) Anticuerpos anti-phf-tau y usos de estos.
MD4716C1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
MX2018000347A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
MX2019010802A (es) Anticuerpos anti-par2 y usos de los mismos.
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
WO2017049038A3 (en) Anti-cd115 antibodies
WO2019005817A3 (en) HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
WO2020121195A8 (en) Trem2 antibodies and uses thereof
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
WO2015187521A3 (en) Anti-blys antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18876749

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18876749

Country of ref document: EP

Kind code of ref document: A2